Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest

Starting soon · Phase 3

Conditions studied: Post-Cardiac Arrest Syndrome

In brief

XePOHCAS: Prospective, randomized, multicenter interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management \[TTM\]) to xenon by inhalation plus standard-of-care post-cardiac arrest intensive care (including TTM).

Key facts

Study ID

NCT03176186

Run by

Invero Pharma, Inc.

People needed

1436

Starts

2026-03-01

Expected to finish

2030-05-01

Last updated by the study team

2025-04-03

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age at least 18 years but less than or equal to 80 years
• Presumed cardiac cause of arrest
• Sustained (>20 minutes) spontaneous circulation upon arrival in the emergency department
• No response to verbal commands on arrival to emergency department and prior to randomization (Glasgow Coma Scale score of <8)
• Attending decision that patient is eligible for TTM

You may not qualify if…

• Written do not attempt resuscitation reported to providers before randomization
• Traumatic etiology of arrest, defined as concomitant blunt, penetrating, or burn-related injury, or uncontrolled bleeding or exsanguination
• Suspected or known stroke or intracranial hemorrhage
• Unwitnessed cardiac arrest
• No-flow (cardiac arrest to initiation of cardiopulmonary resuscitation/defibrillation) time of >10 minutes
• Sustained restoration of spontaneous circulation (ROSC) greater than 30- minutes post-arrest
• Interval from arrival at the emergency department to randomization for intervention of >4 hours.
• Hypothermia (<30°C core temperature)
• Bed-bound prior to cardiac arrest
• Unconsciousness before cardiac arrest (cerebral trauma, spontaneous cerebral hemorrhage, intoxication etc.)
• Coagulopathy
• Systolic arterial pressure <80 mmHg or mean arterial pressure <60 mmHg lasting more than 30 minutes after ROSC
• Known pregnancy
• Have received an investigational drug, device, or biologic product within 30-days
• Known terminal phase of chronic illness
• Hypoxemia (SaO2 <85%) for >15 minutes after ROSC
• Inability to maintain SaO2 >90% on an FiO2 of 50%
• Having any other clinically significant laboratory abnormality, medical condition (such as intrinsic liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator's opinion, makes it inappropriate for the patient to participate in this clinical trial
• Logistically impossible to provide intervention
• Have any condition that would impact the evaluation of modified Rankin Scale (mRS)

Where it is running

• Hartford Hospital — Hartford, Connecticut, United States
• University of Florida — Gainesville, Florida, United States
• Memorial Hospital at Gulfport — Gulfport, Mississippi, United States
• University Nebraska Medical Center — Omaha, Nebraska, United States
• University at Buffalo — Buffalo, New York, United States
• Wexner Medical Center, Ohio State University — Columbus, Ohio, United States
• Baptist Memorial Hospital, Baptist Clinical Research Institute — Memphis, Tennessee, United States
• Houston Methodist Research Institute — Houston, Texas, United States
• Aalborg University Hospital — Aalborg, Denmark
• University Hospital, Rigshospitalet, Blegdamsvej 9 — Copenhagen, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.